Singapore - English - HSA (Health Sciences Authority)

allergan singapore pte. ltd. - tazarotene - cream - 0.1% w/w

India - English - Central Drugs Standard Control Organization

nicholas - tazorotene - gel - 0.05%/0.1% - 15/15;g

Bangladesh - English - DGDA (Directorate General of Drug Administration)

the acme laboratories ltd. - halobetasol propionate + tazarotene - lotion - .01 gm + .045 gm/100 gm

Bangladesh - English - DGDA (Directorate General of Drug Administration)

navana pharmaceuticals ltd. - halobetasol propionate + tazarotene - lotion - .01 gm + .045 gm/100 gm

Bangladesh - English - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd. (dhamrai unit) - halobetasol propionate + tazarotene - lotion - .01 gm + .045 gm/100 gm

United States - English - NLM (National Library of Medicine)

psodex usa inc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) -

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - benzoyl peroxide; clindamycin phosphate -

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - benzoyl peroxide 66.7 mg/g; clindamycin phosphate 12.8 mg/g;   - topical gel - 1%w/w, 5%w/w - active: benzoyl peroxide 66.7 mg/g clindamycin phosphate 12.8 mg/g   excipient: carbomer 940 colloidal silicon dioxide dimeticone disodium edetate dihydrate disodium lauryl sulfosuccinate glycerol poloxamer purified water sodium hydroxide - for the topical treatment of comedo, papular and pustular acne vulgaris.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - benzoyl peroxide - cream - 40 milligram(s)/gram - peroxides; benzoyl peroxide